BACKGROUND: Treatment modifications, including dose-escalations, dose-reductions, switches, discontinuations and restarts of biologics may be necessary in the management of psoriasis but the patterns of usage are incompletely defined.
OBJECTIVES: To examine the treatment utilisation patterns of adalimumab, etanercept and ustekinumab among biologic-naïve and non-naïve psoriasis patients enrolled in the British Association of Dermatologists Biologic Interventions Register (BADBIR).
METHOD: The cohort study included adults with chronic plaque psoriasis who were followed-up for ≥12-months.Treatment modifications were assessed during the first year of therapy. The time-trend method, comparing the cumulative dose (CD) patients received to the recommended cumulative dose (RCD), was used to assess dosing patterns. Concomitant use of other systemic treatments was also examined.
RESULTS: In total, 2980 patients (adalimumab:1675; etanercept:996; ustekinumab:309) were included; 79.2% were biologic-naïve. Over 12-months, 77.4% of patients continued the biologic, 2.6% restarted therapy after a break of ≥90-days, 2.5% discontinued, and 17.5% switched biologic therapy. Most patients (85.7%) received the RCD of the biologic, although 8.1% were exposed to a higher CD. In total, 749(25.1%) patients used conventional systemic therapies concomitantly with a biologic at some stage; methotrexate was used most commonly (458;61.2%). Of those using combination therapy, 454(60.6%) continued the use of the conventional systemic therapy for >120 days after the start of the biologic.
CONCLUSION: More than one-third of patients experienced treatment modifications within the first year of initiating a biologic. Conventional systemic therapies, particularly methotrexate, were commonly used concurrently which should be considered when evaluating treatment response and adverse events to biologics in real-world observational studies. This article is protected by copyright. All rights reserved.